[ad_1]
Synopsis
The government feels the pharmaceutical industry is charging exorbitant prices for anti-cancer drugs. But the solution it has proposed — to cut high trade margins — has drawn flak from the industry. Drug makers argue that even medicines supplied free under patient-assistance programmes have been brought under the ambit of the margin cuts. Mired in legal wrangles, no headway is in sight.
The emperor of maladies begets a kingdom of paupers. When cancer takes its toll, it’s not just the dead that are buried. The patient may pass away, but the treatment often leaves a financially drained family in its wake. At times, a single dose of an anti-cancer drug may cost over one lakh rupees. Not to mention the hospital expenses. This brings up a critical question: Why are these drugs so expensive and what is being done to fix and regulate
BY
ET Prime
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link
